<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286740</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-264-0111</org_study_id>
    <nct_id>NCT01286740</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR</brief_title>
  <official_title>A Phase 2B Open Label Pilot Study to Evaluate Switching From a Regimen Consisting of a Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) STR in Virologically Suppressed, HIV 1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 2b study was to evaluate the efficacy and safety of the
      emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR, after switching
      from the efavirenz (EFV)/FTC/TDF STR at baseline, in maintaining HIV-1 RNA &lt; 50 copies/mL at
      Week 12. HIV-infected patients were enrolled if they had received EFV/FTC/TDF for ≥ 3 months
      prior to study start, were experiencing safety or tolerability concerns (in particular,
      EFV-related intolerance), and wished to change to an alternate, better-tolerated regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 12 (FDA Snapshot Analysis)</measure>
    <time_frame>Week 12</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 12 was analyzed using the FDA snapshot analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 24 (FDA Snapshot Analysis)</measure>
    <time_frame>Week 24</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 24 was analyzed using the FDA snapshot analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48 (FDA Snapshot Analysis)</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 48 was analyzed using the FDA snapshot analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of RPV and EFV at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of RPV and EFV at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of RPV and EFV at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of RPV and EFV at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of RPV and EFV at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of RPV at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of EFV at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The mean (SD) plasma concentration (ng/mL) of EFV was measured at Week 12. No analyses of EFV plasma concentrations were conducted after Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of RPV at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of RPV at Week 36</measure>
    <time_frame>Week 36</time_frame>
    <description>The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of RPV at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 48.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>FTC/RPV/TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/RPV/TDF</intervention_name>
    <description>Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily</description>
    <arm_group_label>FTC/RPV/TDF</arm_group_label>
    <other_name>Complera</other_name>
    <other_name>Eviplera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and sign a written informed consent form

          -  Receiving EFV/FTC/TDF continuously for ≥ 3 months preceding the screening visit

          -  Plasma HIV-1 RNA concentrations (at least two measurements) at undetectable levels for
             ≥ 8 weeks prior to the screening visit and HIV-1 RNA &lt; 50 copies/mL at the screening
             visit

          -  On their first antiretroviral drug regimen, and no HIV-1 RNA &gt; 50 copies/mL measured
             at two consecutive time points after first achieving HIV RNA &lt; 50 copies/mL

          -  Had a genotype prior to starting FTC/RPV/TDF and no known resistance to any of the
             study agents

          -  Normal ECG

          -  Hepatic transaminases (AST and ALT) ≤ 5 x upper limit of normal (ULN)

          -  Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin

          -  Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm^3; platelets ≥
             50,000/mm^3; hemoglobin ≥ 8.5 g/dL)

          -  Serum amylase ≤ 5 x ULN (subjects with serum amylase &gt; 5 x ULN eligible if serum
             lipase ≤ 5 x ULN)

          -  Adequate renal function (estimated glomerular filtration rate ≥ 50 mL/min according to
             the Cockcroft-Gault formula)

          -  Males and Females of childbearing potential must have agreed to utilize highly
             effective contraception methods (two separate forms of contraception, one of which
             must be an effective barrier method, or be nonheterosexually active, practice sexual
             abstinence, or have a vasectomized partner) from screening throughout the duration of
             the study period and for 60 days following the last dose of study drug.

          -  Age ≥ 18 years

          -  Life expectancy ≥ 1 year

        Exclusion Criteria:

          -  A new AIDS-defining condition diagnosed within 21 days prior to screening

          -  Females who were breastfeeding

          -  Positive serum pregnancy test (female of childbearing potential)

          -  Proven or suspected acute hepatitis in the 21 days prior to study entry

          -  Subjects receiving drug treatment for Hepatitis C, or subjects anticipated to receive
             treatment for Hepatitis C during the course of the study, or with a history of liver
             disease

          -  Was experiencing decompensated cirrhosis

          -  Implanted defibrillator or pacemaker

          -  Current alcohol or substance abuse judged by the Investigator to potentially interfere
             with subject compliance

          -  History of malignancy within the past 5 years or ongoing malignancy other than
             cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous
             squamous carcinoma

          -  Active, serious infections requiring parenteral antibiotic or antifungal therapy
             within 21 days prior to Baseline

          -  All investigational drugs

          -  Ongoing therapy or anticipated need to initiate drugs or herbal/natural supplements
             during the study that were contraindicated or not recommended for use as indicated in
             the protocol, including drugs not to be used with FTC, RPV, and TDF; or subjects with
             known allergies to the excipients of the FTC/RPV/TDF STR

          -  Participation in any other clinical trial without prior approval from the sponsor was
             prohibited while participating in this trial

          -  Treatment with immunosuppressant therapies or chemotherapeutic agents within 3 months
             of study screening, or expected to receive these agents or systemic steroids during
             the study (eg, corticosteroids, immunoglobulins, and other immune- or cytokine-based
             therapies)

          -  Any other clinical condition or prior therapy that, in the opinion of the
             Investigator, would make the subject unsuitable for the study or unable to comply with
             the dosing requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Pugatch, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Living Hope Clinical Foundation</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter J. Ruane MD Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anthony Mills MD, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Playa Medical Group and Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dupont Circle Physicians Group, P.C.</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whitman Walker Clinic</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Medical Associates, PC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Kinder Medical Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta ID Group</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Specialists of Atlanta</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northstar Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative of New England</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Be Well Medical Center, P.C.</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton Healthcare, Inc.</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Infectious Disease Clinical Research, Inc.</name>
      <address>
        <city>Addison</city>
        <state>Texas</state>
        <zip>75001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Shalit, M.D.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2011</study_first_submitted>
  <study_first_submitted_qc>January 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <results_first_submitted>March 8, 2013</results_first_submitted>
  <results_first_submitted_qc>March 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 19, 2013</results_first_posted>
  <disposition_first_submitted>December 12, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>December 13, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 18, 2012</disposition_first_posted>
  <last_update_submitted>April 19, 2013</last_update_submitted>
  <last_update_submitted_qc>April 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>HIV</keyword>
  <keyword>Treatment Experienced</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 18 sites in the United States. The first participant was screened on 27 January 2011. The last participant observation was on 26 June 2012.</recruitment_details>
      <pre_assignment_details>63 participants were screened, 50 were enrolled; 49 participants were treated, and comprise the Safety Analysis set. Participants in the Safety Analysis Set who had no major protocol violation comprise the Full Analysis Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FTC/RPV/TDF</title>
          <description>Participants switched from their existing treatment regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (tenofovir DF; TDF) to the FTC 200 mg/rilpivirine (RPV) 25 mg/TDF 300 mg single-table regimen (STR).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled and Treated</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 12 (Primary Endpoint)</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Enrolled but not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set: participants who enrolled and received at least one dose of study drug</population>
      <group_list>
        <group group_id="B1">
          <title>FTC/RPV/TDF</title>
          <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HIV-1 RNA Category</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 50 Copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 to &lt; 400 Copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EFV plasma concentration</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2204.9" spread="1059.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 12 (FDA Snapshot Analysis)</title>
        <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 12 was analyzed using the FDA snapshot analysis.</description>
        <time_frame>Week 12</time_frame>
        <population>Full Analysis Set: participants who were enrolled into the study, received at least one dose of study drug and had no major protocol violation</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/RPV/TDF</title>
            <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 12 (FDA Snapshot Analysis)</title>
          <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 12 was analyzed using the FDA snapshot analysis.</description>
          <population>Full Analysis Set: participants who were enrolled into the study, received at least one dose of study drug and had no major protocol violation</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 24 (FDA Snapshot Analysis)</title>
        <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 24 was analyzed using the FDA snapshot analysis.</description>
        <time_frame>Week 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/RPV/TDF</title>
            <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 24 (FDA Snapshot Analysis)</title>
          <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 24 was analyzed using the FDA snapshot analysis.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48 (FDA Snapshot Analysis)</title>
        <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 48 was analyzed using the FDA snapshot analysis.</description>
        <time_frame>Week 48</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/RPV/TDF</title>
            <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48 (FDA Snapshot Analysis)</title>
          <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 48 was analyzed using the FDA snapshot analysis.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of RPV and EFV at Week 1</title>
        <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 1.</description>
        <time_frame>Week 1</time_frame>
        <population>Participants with evaluable measurements for plasma concentrations of RPV and EFV at Week 1 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/RPV/TDF</title>
            <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of RPV and EFV at Week 1</title>
          <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 1.</description>
          <population>Participants with evaluable measurements for plasma concentrations of RPV and EFV at Week 1 were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RPV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EFV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.5" spread="234.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of RPV and EFV at Week 2</title>
        <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 2.</description>
        <time_frame>Week 2</time_frame>
        <population>Participants with evaluable measurements for plasma concentrations of RPV and EFV at Week 2 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/RPV/TDF</title>
            <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of RPV and EFV at Week 2</title>
          <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 2.</description>
          <population>Participants with evaluable measurements for plasma concentrations of RPV and EFV at Week 2 were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RPV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="24.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EFV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" spread="86.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of RPV and EFV at Week 4</title>
        <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 4.</description>
        <time_frame>Week 4</time_frame>
        <population>Participants with evaluable measurements for plasma concentrations of RPV and EFV at Week 4 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/RPV/TDF</title>
            <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of RPV and EFV at Week 4</title>
          <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 4.</description>
          <population>Participants with evaluable measurements for plasma concentrations of RPV and EFV at Week 4 were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RPV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5" spread="33.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EFV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="17.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of RPV and EFV at Week 6</title>
        <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 6.</description>
        <time_frame>Week 6</time_frame>
        <population>Participants with evaluable measurements for plasma concentrations of RPV and EFV at Week 6 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/RPV/TDF</title>
            <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of RPV and EFV at Week 6</title>
          <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 6.</description>
          <population>Participants with evaluable measurements for plasma concentrations of RPV and EFV at Week 6 were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RPV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8" spread="36.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EFV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of RPV and EFV at Week 8</title>
        <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 8.</description>
        <time_frame>Week 8</time_frame>
        <population>Participants with evaluable measurements for plasma concentration of RPV and EFV at Week 8 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/RPV/TDF</title>
            <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of RPV and EFV at Week 8</title>
          <description>The mean (SD) plasma concentration (ng/mL) of RPV and EFV was measured at Week 8.</description>
          <population>Participants with evaluable measurements for plasma concentration of RPV and EFV at Week 8 were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RPV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" spread="35.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EFV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Values were below the limit of quantitation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of RPV at Week 12</title>
        <description>The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 12.</description>
        <time_frame>Week 12</time_frame>
        <population>Participants with measurements for plasma concentration of RPV at Week 12 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/RPV/TDF</title>
            <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of RPV at Week 12</title>
          <description>The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 12.</description>
          <population>Participants with measurements for plasma concentration of RPV at Week 12 were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.0" spread="54.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of EFV at Week 12</title>
        <description>The mean (SD) plasma concentration (ng/mL) of EFV was measured at Week 12. No analyses of EFV plasma concentrations were conducted after Week 12</description>
        <time_frame>Week 12</time_frame>
        <population>Participants with evaluable measurements for plasma concentration of EFV at Week 12 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/RPV/TDF</title>
            <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of EFV at Week 12</title>
          <description>The mean (SD) plasma concentration (ng/mL) of EFV was measured at Week 12. No analyses of EFV plasma concentrations were conducted after Week 12</description>
          <population>Participants with evaluable measurements for plasma concentration of EFV at Week 12 were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" spread="186.46">Interquartile range values were below the limit of quantitation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of RPV at Week 24</title>
        <description>The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 24.</description>
        <time_frame>Week 24</time_frame>
        <population>Participants with evaluable measurements for plasma concentration of RPV at Week 24 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/RPV/TDF</title>
            <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of RPV at Week 24</title>
          <description>The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 24.</description>
          <population>Participants with evaluable measurements for plasma concentration of RPV at Week 24 were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1" spread="37.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of RPV at Week 36</title>
        <description>The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 36.</description>
        <time_frame>Week 36</time_frame>
        <population>Participants with evaluable measurements for plasma concentration of RPV at Week 36 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/RPV/TDF</title>
            <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of RPV at Week 36</title>
          <description>The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 36.</description>
          <population>Participants with evaluable measurements for plasma concentration of RPV at Week 36 were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" spread="34.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of RPV at Week 48</title>
        <description>The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 48.</description>
        <time_frame>Week 48</time_frame>
        <population>Participants with evaluable measurements for plasma concentration of RPV at Week 48 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FTC/RPV/TDF</title>
            <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of RPV at Week 48</title>
          <description>The mean (SD) plasma concentration (ng/mL) of RPV was measured at Week 48.</description>
          <population>Participants with evaluable measurements for plasma concentration of RPV at Week 48 were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" spread="34.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to Week 48</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FTC/RPV/TDF</title>
          <description>Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosures</name_or_title>
      <organization>Gilead Sciences, Inc.</organization>
      <email>ClinicalTrialDisclosures@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

